首页> 外文期刊>The journal of sexual medicine >Improvement in sexual quality of life of the female partner following vardenafil treatment of men with erectile dysfunction: a randomized, double-blind, placebo-controlled study.
【24h】

Improvement in sexual quality of life of the female partner following vardenafil treatment of men with erectile dysfunction: a randomized, double-blind, placebo-controlled study.

机译:伐地那非治疗男性勃起功能障碍患者后,改善女性伴侣的性生活质量:一项随机,双盲,安慰剂对照研究。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: Erectile dysfunction (ED) impacts on both members of the couple. Female partners of men with ED are more likely to report reduced sexual quality of life than women whose partners do not have ED. AIM: To assess vardenafil efficacy in men with ED and determine the effects of treatment on their female partner's sexual quality of life. METHODS: Study participants comprised men aged 18-64 years with ED and their female partners. Eligible men had ED of >/=6 months' duration and a female partner who was motivated to support their ED treatment. Eligible women had a total Female Sexual Function Index score >23.55, indicating absence of significant sexual dysfunction. Following a 4-week screening period, men were randomized to treatment with vardenafil 10 mg or placebo, which could be titrated to 20 or 5 mg after 4 weeks. MAIN OUTCOMES MEASURES: Primary efficacy variables were question 3 of the Sexual Encounter Profile questionnaire (SEP3) and the quality-of-life domain of the modified Sexual Life Quality Questionnaire (mSLQQ-QOL). RESULTS: The intent-to-treat population included 343 couples, with 168 and 175 men receiving vardenafil or placebo, respectively. Vardenafil treatment significantly improved both erection maintenance and the female partners' sexual quality of life. Least squares (LS) mean SEP3 overall success rates after 12 weeks of treatment were 9.5 (baseline) vs. 67.2 (week 12) and 12.4 (baseline) vs. 24.2 (week 12) in the vardenafil and placebo groups, respectively (P < 0.0001). In female partners, LS mean mSLQQ-QOL scores were 28.8 (baseline) vs. 68.2 (last observation carried forward [LOCF]) in the vardenafil group and 24.6 (baseline) vs. 40.5 (LOCF) in the placebo group (P < 0.0001). CONCLUSIONS: Vardenafil treatment of men with ED improved both their erectile function and the sexual quality of life of their female partners.
机译:简介:勃起功能障碍(ED)对夫妻双方都有影响。与没有ED的女性相比,患有ED的男性的女性伴侣更有可能报告性生活质量下降。目的:评估伐地那非对患有ED的男性的疗效,并确定治疗对女性伴侣性生活质量的影响。方法:研究参与者包括年龄在18-64岁的ED及其女性伴侣。符合条件的男性的ED持续时间> / = 6个月,并且女性伴侣的动机是支持其ED治疗。符合条件的女性的女性性功能指数总得分> 23.55,表明没有明显的性功能障碍。经过4周的筛选后,将男性随机分配接受10 mg伐地那非或安慰剂治疗,4周后可将其滴定至20或5 mg。主要观察指标:主要疗效变量是“性相遇档案”问卷(SEP3)的问题3和经修改的“性生活质量问卷”(mSLQQ-QOL)的生活质量范围。结果:意向性治疗人群包括343对夫妇,分别有168和175名男性接受伐地那非或安慰剂治疗。伐地那非治疗显着改善了勃起维持和女性伴侣的性生活质量。伐得那非和安慰剂组在治疗12周后的最小二乘(LS)平均SEP3总成功率分别为9.5(基线)对67.2(12周)和12.4(基线)对24.2(12周)(P <2) 0.0001)。在女性伴侣中,伐地那非组的LS平均mSLQQ-QOL得分为28.8(基线)对68.2(最近一次结转[LOCF]),安慰剂组为24.6(基线)对40.5(LOCF)(P <0.0001) )。结论:伐地那非治疗患有ED的男性可改善其勃起功能和女性伴侣的性生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号